PORTO, Portugal — The European Union cemented its support for Pfizer-BioNTech and its novel COVID-19 vaccine technology Saturday by agreeing to a massive contract extension for a potential 1.8 billion doses through 2023.
EU Commission President Ursula von der Leyen said her office has approved a contract for a guaranteed 900 million doses with the same amount of doses as a future option.
The new contract, which has the unanimous backing of the 27 EU member nations, will entail not only the production of the vaccines but also making sure that all the essential components are sourced from the EU.
The European Commission currently has a portfolio of 2.6 billion doses from half a dozen companies.
Pfizer-BioNTech had an initial contract of 600 million doses with the EU.
Saturday’s announcement also underscores the confidence the EU has shown in the technology behind the Pfizer-BioNTech vaccine, which is different from how the Oxford-AstraZeneca vaccine works.
“But of course, we will also explore other contracts, for example, based on other technologies like the protein-based technologies. The key point is to keep our options open,” von der Leyen said at an EU summit in Portugal.
The active ingredient in the Pfizer-BioNTech shot is messenger RNA, or mRNA, which contains the instructions for human cells to construct a harmless piece of the coronavirus called the spike protein.
The human immune system recognizes the spike protein as foreign, allowing it to mount a response against the virus upon infection.